How Does Pharmacogenomics Strengthen Healthcare?

The pharmacogenomics industry has garnered $5,527.2 million revenue in 2021, and it is projected to generate $10,505.3 million revenue, advancing at a rate of 7.4% in the coming future.

To learn more about this report: https://bit.ly/43sUv1S

Pharmacogenomics can be defined as the study of the genes that affect an individual’s response to drugs. It is combined of pharmacology and genomics, which involves developing effective safe medications relying on the genetic makeup of the person. 

Pharmacogenomics focuses on tailoring medical treatment for each person or group of people. It shows how DNA affects the individuals’ response to drugs. In several cases, DNA can affect whether the drug is ineffective, or have a bad reaction to the drug, or gives no effect. 

Pharmacogenomics can help in enhancing health by giving you prior knowledge on the effect of the drug, and if it will be safe for intake. 

How Does Pharmacogenomics Function? 

Drugs interact with the body in various ways, relying on how the drug is taken, and where it will act in the body. After consuming the drug, the body requires to break it down and get it to the intended area. 

The DNA can impact various steps in this process to affect the response of the drug. Several examples of such interactions are provided below: 

Drug Receptors: Several drugs require to be attached to the proteins on the surface of cells, usually known as receptors to work effectively. Your DNA takes care of the types of receptors you have, and the number of receptors, that impacts the response to the drug. You may require a lower or higher drug amount than most people, or a different drug. 

Breast Cancer and T-DM1.: Several breast cancers form massive HER2, and the excess of HER2 makes cancer propel and spread. T-DM1, the drug can help in treating breast cancer, as it attaches HER2 on cancerous cells, and destroys them. If you are suffering from breast cancer, then you need to get the sample of the tumor tested, to determine if T-DM1 can provide the appropriate treatment. 

Drug Uptake: It requires taking several drugs actively into the cells and tissues, in which they act. DNA can impact the uptake of several drugs. The decreased uptake could mean that it does not work effectively, and it may cause build-up in the other parts of the body. The quick removal of these drugs from cells may result in not having time to act. 

Drug Breakdown: The DNA impacts how the body breaks down the drug. If a drug breaks down more quickly compare to other people, the body gets relieved from the drug early and may require more of it or a different drug. If the body breaks down the drug slowly, then you require less drug. 

The major players operating in the industry include:

1- F. Hoffmann-La Roche Ltd.

2- Mesa Laboratories Inc.

3- QIAGEN N.V.

4- Abbott Laboratories

5- Laboratory Corporation of American Holdings

6- Exact Sciences Corporation. 

Therefore, pharmacology poses great prominence in treating various diseases and disorders depending on the response of a person’s DNA to drugs.  

Read More

How are Increasing Government Initiatives Driving Genomics Market?

According to a study conducted by P&S Intelligence, the global genomics market is expected to generate a revenue of $68.0 billion by 2030, increasing from $18.2 billion in 2019, progressing at a 12.7% CAGR during the forecast period (2020–2030). The market is growing due to the increasing government initiatives and support, rising requirement for personalized medicine, and reduction in the cost of sequencing services. In terms of solution, the market is categorized into services, consumables, and instruments, among which, the consumables category dominated the market in 2019. 

To learn more about this report: https://bit.ly/3hUkiH2

This can be attributed to the rising number of samples that are being processed at labs, research centers, and several other end-use settings. In addition to this, the growing number of research projects are also resulting in the rising demand for consumables. On the basis of application, the genomics market is categorized into diagnostics, agriculture and animal research, precision medicine, and drug discovery & development. Among which, the diagnostics category held the major share of the market in 2019, owing to the rising research projects related to genetic diseases, including cancer.

North America accounted for the largest share of the market in the past, which is because of the various ongoing genomics research projects, presence of major players, and increasing investments in the industry by both government and private organizations. The Asia-Pacific region is predicted to register the highest CAGR during the forecast period, as the number of research activities in the field to genomics is growing in countries including Japan, India, and China. Both public and private organizations are providing funding for innovations in genome research. 

Browse full report at: https://www.psmarketresearch.com/market-analysis/genomics-market-revenue

The increasing initiatives and support by governments is a key factor leading to the growth of the genomics market. For example, the government of India announced in 2019 that the country would launch its first human genome mapping project along with the Department of Biotechnology for helping researchers get closer to the development of effective therapies for critical illnesses, including cancer. Under the project, 20,000 Indian genomes are expected to be scanned for developing diagnostic tests and enhanced therapies for managing diseases.

In conclusion, the market is being driven by increasing need for personalized medicine and rising support and initiatives by governments across the globe.

Read More